Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

Lu, S. X., Wang, E., Pastore, A., Chen, X. F., Imig, J., Lee, S. C., Ghebrechristos, Y., Yoshimi, A., Bitner, L. E., Ki, M., Kloetgen, A., Lin, K. T., Tibes, R., Krainer, A. R., Uehara, T., Owa, T., Aifantis, I., Abdel-Wahab, O. I. (November 2018) Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms. Blood, 132 (Supple). Meeting Abstract 427. ISSN 0006-4971

Abstract

RNA-binding proteins (RBPs) regulate many aspects of transcription and translation in a cell- and tissue-specific manner and are frequently dysregulated in malignancy. We systematically evaluated RBPs preferentially required in acute myeloid leukemia (AML) over other forms of cancer or normal hematopoietic precursors using a CRISPR/Cas9 domain-based, loss-of-function screen targeting 490 classical RBPs with 2,900 sgRNAs (Fig. A). This screen was performed in cells lines representing AML, T-cell acute lymphoblastic leukemia (T-ALL), and lung adenocarcinoma (LUAD) and revealed multiple RBPs preferentially required for AML survival, but not for T-ALL or LUAD survival. We identified genes encoding 21 RBPs that were >3-fold depleted in AML cells and significantly overexpressed in AML patient samples versus normal adult CD34+ precursors (p-value < 0.05; Fig. B).

Item Type: Paper
Subjects: Publication Type > Meeting Abstract
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > RNA binding protein
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > RNA splicing
CSHL Authors:
Communities: CSHL labs > Krainer lab
Depositing User: Matthew Dunn
Date: 29 November 2018
Date Deposited: 25 Mar 2019 14:55
Last Modified: 25 Mar 2019 14:55
URI: https://repository.cshl.edu/id/eprint/37748

Actions (login required)

Administrator's edit/view item Administrator's edit/view item